Sichuan University
Clinical trials sponsored by Sichuan University, explained in plain language.
-
New radiation combo aims to boost immunotherapy in advanced lung cancer
Disease control OngoingThis early-phase trial tests whether adding low-dose radiation and targeted radiation (SBRT) to an immunotherapy drug (PD-1 inhibitor) is safe for people with stage IV non-small cell lung cancer who have not responded to standard treatments. About 9 participants will receive the …
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for aggressive lung cancer: drug cocktail plus Low-Dose radiation shows promise
Disease control OngoingThis study tests a new combination treatment for people with extensive-stage small cell lung cancer who have not had prior therapy. It combines an experimental immunotherapy (AK104) with standard chemotherapy and low-dose radiation to see if it can better control the cancer. The …
Phase: PHASE1, PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Triple threat: Low-Dose radiation plus chemo and immunotherapy takes on tough lung cancer
Disease control OngoingThis phase 2 trial is testing a new approach for people with extensive-stage small cell lung cancer who have not had prior treatment. It combines low-dose radiation with standard chemotherapy (cisplatin or carboplatin plus etoposide) and the immunotherapy drug serplulimab. The go…
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Lung cancer combo therapy study pulled before starting
Disease control TerminatedThis early-stage study aimed to test a new combination treatment for people with extensive-stage small cell lung cancer who had not received prior therapy. The approach combined low-dose radiation with standard chemotherapy and two immunotherapy drugs (toripalimab and tifcemalima…
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC